China Money Network
Login
Join

Bioventure Leads Series A+ Round In Antiviral Drugs Maker Ark Biosciences

  • February 6, 2017 — 14:13 CST

This Data Is Locked!

This area is available only to Subscribers.

Chinese medical and pharmaceutical-focused venture fund Bioventure Investment Management Ltd. has led an undisclosed series A+ round in Ark Biosciences, a Shanghai-based drug developer targeting... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Join

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?

Login
Related Topics:

Related Data: